The Heat is on for First Circle Medical
This article was originally published in Start Up
Executive Summary
Many scientists and physicians believe in the healing power of heat, but to date, there have been no major commercial successes in hyperthermia. Hyperthermia companies suffer from the field's checkered past: a wave of commercial hyperthermia flameouts in the 1980's means that many investors won't give hyperthermia companies a second glance. First Circle Medical's challenge is to win over skeptical investors and clinicians as it pursues a new device market for hepatitis C. There it aims to offer a side effect free alternative to drugs for a deadly and prevalent disease with few therapeutic options, or, at the very least, a procedure that will potentially boost the efficacy of drugs. But as the first and only player in a new field, and in light of the prejudice against hyperthermia devices that many share, First Circle has to create a base of rigorous scientific data from scratch; indeed, it has to bear the burden of doing everything right.
You may also be interested in...
Making the Most of Incremental Advantages in the Hepatitis C Market
Schering-Plough's largest drug--a combination of PEG-INTRON (peginterferon alfa-2b) and Rebetol (ribavirin) for hepatitis C--has enjoyed an enormous and growing market to itself. Now, though, Roche is about to challenge Schering-Ploughy's hegemony. Roche has fired the first volley in a battle that will be based as much on marketing as on clinical features and benefits; it has priced its ribavirin at 43% below that of SGP's version.
Liver Roll-Ups? (Not the Deli Kind)
Merchant bank The Aethena Group aims to provide a new kind of resource to emerging and middle market companies that need a boost to get to a valuation level that supports investment by traditional investors. One field in need of such support, Aethena believes, is liver disease, which represents enormous untapped markets, but product risk associated with an evolving understanding of liver biology. Aethena hopes to offer strategic options to companies in this industry.
Liver Roll-Ups? (Not the Deli Kind)
Merchant bank The Aethena Group aims to provide a new kind of resource to emerging and middle market companies that need a boost to get to a valuation level that supports investment by traditional investors. One field in need of such support, Aethena believes, is liver disease, which represents enormous untapped markets, but product risk associated with an evolving understanding of liver biology. Aethena hopes to offer strategic options to companies in this industry.